Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

Movement Disorders

Volumn 18, Issue 6, 2003, Pages 683-685

  Ondo, William G ^a   Hunter, Christine ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Basal ganglia; Flumazenil; Parkinson's disease; Therapeutic trial

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMANTADINE; FLUMAZENIL; LEVODOPA; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GABAERGIC SYSTEM; GAIT; HAND MOVEMENT; HUMAN; MALE; NEUROLOGIC EXAMINATION; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; VELOCITY;

AGED; ANTIPARKINSON AGENTS; FEMALE; FLUMAZENIL; GABA ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC;

EID: 0038084254     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10426     Document Type: Article

References (20)

1. Philip B. Drug reversal: benzodiazepine receptors and antagonists. J Clin Anesth 1993;5(Suppl.):46S-51S.
2. Karavokiros KAT, Tsipsis GB. Flumazenil: a benzodiazepine antagonist. Ann Pharmacol 1990;24:976-981.
3. Heniff MS, Moore GP, Trout A, Cordell WH, Nelson DR. Comparison of routes of flumazenil administration to reverse midazolam-induced respiratory depression in a canine model. Acad Emerg Med 1997;4:1115-1118.
4. Scheepers LD, Montgomery CJ, Kinahan AM, Dunn GS, Bourne RA, McCormack JP. Plasma concentration of flumazenil following intranasal administration in children. Can J Anaesth 2000;47:120-124.
5. Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991;42:1061-1089.
6. 11C]-labeled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatric Res 1985;19:609-622.
7. 11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. Eur J Pharmacol 1985;110:247-251.
8. 11C]flumazenil positron emission tomography abnormalities of thalamic nuclei in temporal lobe epilepsy. Neurology 1999;53:2037-2045.
9. Rothstein JD, Guidotti A, Tinuper P, et al. Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor. Lancet 1992;340:1002-1004.
10. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:142-151.
11. Vila M, Herrero MT, Levy R, et al. Consequences of nigrostriatal denervation on the γ-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 1996;46:802-809.
12. Bartholini G, Stadler H. Cholinergic and GABAergic influences on the dopamine release in extrapyramidal centers. In: Almgren O, Carlson A, Engel J, editors. Regulation of catecholamine turnover. Amsterdam: North-Holland; 1976. p 235-242.
13. 3H-acetylcholine release evoked by excitatory amino acids. Nature 1982;297:422-424.
14. Scatton B, Zivkovic B, Dedek J, Lloyd KG, Constantinidis J, Tissot R, Bartholini G. γ-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J Pharmacol Exp Ther 1982;220:678-688.
15. Lloyd KG, Worms P, Scatton B, et al. The influence of GABA on dopamine neuron activity. In: Langer SZ, Starke L, Dubocovitch ML, editors. Presynaptic receptors. New York: Pergamon Press; 1979. p 207-212.
16. Bartholini G, Stadler H. Evidence for intrastriatal GABAergic influence on dopaminergic neurons in the cat. Neuropharmacology 1977;16:343-347.
17. Bartholini G, Stadler H, Gader-Ciria M, Lloyd KG. The use of the push-pull canula to estimate the dynamics of acetylcholamine and catecholamines within various brain areas. Neuropharmacology 1979;15:515-519.
18. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992;32:151-161.
19. Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, Brooks DJ. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749-757.
20. Palmieri MG, Iani C, Scalise A, Desiato MT, Loberti M, Telera S, Caramia MD. The effect of benzodiazepines and flumazenil on motor cortical excitability in the human brain. Brain Res 1999; 815:192-199.